Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network.
暂无分享,去创建一个
Janneth González | George E Barreto | Alexander Rodríguez-López | G. Barreto | Janneth González | Carlos J Alméciga-Díaz | Alexander Rodríguez-López | C. Alméciga-Díaz | Diego A Salazar | Angélica Herreño | Hector Barbosa | Juliana Herrera | Andrea Ardila | Andrea Ardila | A. Herreño | D. A. Salazar | H. Barbosa | Juliana Herrera | J. Herrera
[1] N. Karabul,et al. Mucopolysaccharidoses and other lysosomal storage diseases. , 2013, Rheumatic diseases clinics of North America.
[2] Markus J. Herrgård,et al. Analysis of Genetic Variation and Potential Applications in Genome-Scale Metabolic Modeling , 2015, Front. Bioeng. Biotechnol..
[3] David M Eddy,et al. Archimedes: a trial-validated model of diabetes. , 2003, Diabetes care.
[4] T. Lehman,et al. Diagnosis of the mucopolysaccharidoses. , 2011, Rheumatology.
[5] M. Mattson,et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Clarke. The mucopolysaccharidoses: a success of molecular medicine , 2008, Expert Reviews in Molecular Medicine.
[7] J. Muenzer. Overview of the mucopolysaccharidoses. , 2011, Rheumatology.
[8] P. Morlière,et al. Oxidative stress is independent of inflammation in the neurodegenerative sanfilippo syndrome type B , 2015, Journal of neuroscience research.
[9] J. Esko,et al. Glycan-based biomarkers for mucopolysaccharidoses. , 2014, Molecular genetics and metabolism.
[10] V. Valayannopoulos,et al. Therapy for the mucopolysaccharidoses. , 2011, Rheumatology.
[11] R. Giugliani. Mucopolysacccharidoses: From understanding to treatment, a century of discoveries , 2012, Genetics and molecular biology.
[12] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[13] A. Haimovitz-Friedman,et al. Ceramide signaling in apoptosis. , 1996, British medical bulletin.
[14] M. Haskins,et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. , 2008, The American journal of pathology.
[15] P. Boya. Lysosomal function and dysfunction: mechanism and disease. , 2012, Antioxidants & redox signaling.
[16] Roberto Giugliani,et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. , 2015, Biochimica et biophysica acta.
[17] Bernhard O. Palsson,et al. A detailed genome-wide reconstruction of mouse metabolism based on human Recon 1 , 2010, BMC Systems Biology.
[18] Edda Klipp,et al. Systems Biology , 1994 .
[19] S. Walkley. Pathogenic cascades in lysosomal disease—Why so complex? , 2009, Journal of Inherited Metabolic Disease.
[20] Nagasuma R. Chandra,et al. Flux balance analysis of biological systems: applications and challenges , 2009, Briefings Bioinform..
[21] A. Tessitore,et al. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI , 2009, PathoGenetics.
[22] Jens Nielsen,et al. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling , 2014, Front. Genet..
[23] W. Sly,et al. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. , 2003, Human molecular genetics.
[24] Rainer Breitling,et al. What is Systems Biology? , 2010, Front. Physiology.
[25] S. Tomatsu,et al. Adeno‐associated virus gene transfer in Morquio A disease – effect of promoters and sulfatase‐modifying factor 1 , 2010, The FEBS journal.
[26] J. Nicholson,et al. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. , 2014, Gastroenterology.
[27] D. Kell,et al. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery☆ , 2014, Drug discovery today.
[28] S. Alves,et al. Glycosaminoglycan Storage Disorders: A Review , 2011, Biochemistry research international.
[29] F. Platt,et al. Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases* , 2010, The Journal of Biological Chemistry.
[30] Ronan M. T. Fleming,et al. A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.
[31] A. Ballabio,et al. Lysosome: regulator of lipid degradation pathways , 2014, Trends in cell biology.
[32] M. Haskins. Animal models for mucopolysaccharidosis disorders and their clinical relevance , 2007, Acta paediatrica.
[33] E. Ruppin,et al. Predicting metabolic biomarkers of human inborn errors of metabolism , 2009, Molecular systems biology.
[34] J. Loor,et al. Application of Top-Down and Bottom-up Systems Approaches in Ruminant Physiology and Metabolism , 2012, Current genomics.
[35] V. G. Pereira,et al. Evidence of lysosomal membrane permeabilization in mucopolysaccharidosis type I: Rupture of calcium and proton homeostasis , 2010, Journal of cellular physiology.
[36] U. Brunk,et al. Lysosomes in iron metabolism, ageing and apoptosis , 2008, Histochemistry and Cell Biology.
[37] J. Hopwood,et al. Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes. , 1998, The Journal of clinical investigation.
[38] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[39] Inyoul Y. Lee,et al. A systems approach to prion disease , 2009, Molecular systems biology.
[40] A. Ballabio,et al. Lysosomal disorders: from storage to cellular damage. , 2009, Biochimica et biophysica acta.
[41] T. Shimada,et al. Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses , 2014, Metabolites.
[42] E. Shapira. Biochemical genetics : a laboratory manual , 1989 .
[43] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[44] Masaru Tomita,et al. Systems Biology, Metabolomics, and Cancer Metabolism , 2012, Science.
[45] A. Ballabio,et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB , 2012, The EMBO journal.
[46] Ronan M. T. Fleming,et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.
[47] R. Giugliani,et al. Biomarkers for the mucopolysaccharidoses: discovery and clinical utility. , 2012, Molecular genetics and metabolism.
[48] P. Schwille,et al. Lipids as Modulators of Proteolytic Activity of BACE , 2005, Journal of Biological Chemistry.
[49] Ines Thiele,et al. Computationally efficient flux variability analysis , 2010, BMC Bioinformatics.
[50] E. Diamandis,et al. Tissue culture‐based breast cancer biomarker discovery platform , 2008, International journal of cancer.
[51] H. Galjaard,et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). , 1990, Clinica chimica acta; international journal of clinical chemistry.
[52] A. Jegga,et al. Systems biology of the autophagy-lysosomal pathway , 2011, Autophagy.
[53] Jeffrey D Orth,et al. What is flux balance analysis? , 2010, Nature Biotechnology.
[54] J. Muenzer,et al. Evaluation of disease severity in mucopolysaccharidoses. , 2010, Journal of pediatric rehabilitation medicine.
[55] Mohd Saberi Mohamad,et al. Database and tools for metabolic network analysis , 2014, Biotechnology and Bioprocess Engineering.
[56] M. Sands,et al. Metabolic Adaptations to Interrupted Glycosaminoglycan Recycling* , 2009, The Journal of Biological Chemistry.
[57] Osbaldo Resendis-Antonio,et al. Modeling metabolism: a window toward a comprehensive interpretation of networks in cancer. , 2015, Seminars in cancer biology.
[58] Zachary A. King,et al. Constraint-based models predict metabolic and associated cellular functions , 2014, Nature Reviews Genetics.
[59] B. Palsson,et al. A protocol for generating a high-quality genome-scale metabolic reconstruction , 2010 .
[60] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[61] C. Semenkovich,et al. Lysosomal Dysfunction Results in Altered Energy Balance* , 2007, Journal of Biological Chemistry.
[62] Monica L. Mo,et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.
[63] Alexander V. Ratushny,et al. Systems cell biology , 2014, The Journal of cell biology.
[64] B. Kholodenko,et al. Systems medicine: helping us understand the complexity of disease. , 2013, QJM : monthly journal of the Association of Physicians.
[65] P. Fitzpatrick,et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB , 2014, Proceedings of the National Academy of Sciences.
[66] M. Wendeler,et al. Hexosaminidase assays , 2008, Glycoconjugate Journal.
[67] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[68] A. Pshezhetsky,et al. Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. , 2015, Brain : a journal of neurology.
[69] Xiaowei Yang,et al. Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine , 2014, PLoS Comput. Biol..
[70] R. Kutner,et al. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors , 2009, Nature Protocols.
[71] Aleksander S Popel,et al. Computational systems biology approaches to anti-angiogenic cancer therapeutics. , 2015, Drug discovery today.
[72] Ronan M. T. Fleming,et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.
[73] E. Ruppin,et al. Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.
[74] Maria P. Pavlou,et al. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.
[75] U. Brunk,et al. Linköping University Postprint LYSOSOMES IN IRON METABOLISM , AGEING AND APOPTOSIS , 2008 .
[76] J. Convit,et al. Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. , 1975, The Biochemical journal.
[77] S. Emr,et al. Autophagy as a regulated pathway of cellular degradation. , 2000, Science.
[78] K. Hemsley,et al. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA). , 2014, Molecular genetics and metabolism.
[79] P. Hackett,et al. Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. , 2015, Molecular genetics and metabolism.